Change 5-day change 1-year change 3-year change Capi.($)
-0.26%+0.72%+3.54%+10.05% 50.73B
-2.22%-1.25%+391.53%+593.69% 39.73B
-0.54%+0.39%+27.67%-5.10% 34.69B
-1.36%+0.35%+19.34%+55.53% 33.21B
+1.21%-4.58%+3.00%+31.73% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+66.38%+122.57% 15.37B
+0.35%+0.73%+15.03%+16.81% 13.78B
-0.62%-3.09%+11.43%-31.02% 12.85B
Average -0.53%-0.83%+67.24%+99.28% 27.1B
Weighted average by Cap. -0.65%-0.23%+82.74%+124.74%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-